Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)

This publication has 63 references indexed in Scilit:

• The Evolving Role of Cetuximab in Non–Small Cell Lung Cancer
  Clinical Cancer Research, 2006
• ERBB receptors and cancer: the complexity of targeted inhibitors
  Nature Reviews Cancer, 2005
• Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer
  Journal of Clinical Oncology, 2005
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
  Annals of Oncology, 2002
• The ErbB signaling network: receptor heterodimerization in development and cancer
  The EMBO Journal, 2000
• Augmentation of a humanized Anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225
  Oncogene, 1999
• Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma
  Surgical Oncology, 1994
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogene
  Science, 1987